SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26669
Abstract: Patients with B‐cell malignancies have suboptimal immune responses to SARS‐CoV‐2 vaccination and are a high‐risk population for severe COVID19 disease. We evaluated the effect of a third booster BNT162b2 vaccine on the kinetics of anti‐… read more here.
Keywords: patients cell; booster bnt162b2; cell malignancies; humoral responses ... See more keywords